sEH inhibitors have been indicated as beneficial treatments in animal models of high blood pressure [43,44,46], inflammation [44,48,53], myocardial injury [44,54–56], ischemia–reperfusion [57,58], pathological cardiac hypertrophy [44], and insulin resistance [49,50] and have been shown to protect heart structure and function [59]. This evidence concerns the gene EPHX2 and Insulin resistance.